NRXP $0.38 - Phase 2/3 results imminent should come by end of this month or ealry march .. market cap only $33 million NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Completion of Enrollment of its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression https://www.finanznachrichten.de/nachrichten-2024-01/61194548-nrx-pharmaceuticals-inc-nasdaq-nrxp-announces-completion-of-enrollment-of-its-phase-2b-3-trial-of-nrx-101-in-suicidal-treatment-resistant-bipolar-008.htm Exceeded originally target enrollment (70) with n=74 Last patient, last visit expected in approximately six weeks; data to follow shortly thereafter Positive data triggers milestone payment from Alvogen, as previously announced. company presentation https://www.nrxpharma.com/wp-content/uploads/NRx-Corporate-Presentation.pdf